Frankfurt - Delayed Quote EUR

Mersana Therapeutics, Inc. (0M4.F)

Compare
0.8396
-0.3519
(-29.53%)
At close: January 10 at 4:23:24 PM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
34,837.0000
36,855.0000
26,581.0000
43.0000
828.0000
Operating Expense
114,290.0000
207,812.0000
230,348.0000
168,901.0000
88,938.0000
Operating Income
-79,453.0000
-170,957.0000
-203,767.0000
-168,858.0000
-88,110.0000
Net Non Operating Interest Income Expense
5,751.0000
8,000.0000
-445.0000
-1,202.0000
65.0000
Other Income Expense
--
-8,713.0000
--
--
--
Pretax Income
-74,201.0000
-171,670.0000
-204,212.0000
-170,060.0000
-88,045.0000
Net Income Common Stockholders
-74,619.0000
-171,670.0000
-204,212.0000
-170,060.0000
-88,045.0000
Diluted NI Available to Com Stockholders
-74,619.0000
-171,670.0000
-204,212.0000
-170,060.0000
-88,045.0000
Basic EPS
-0.60
-1.48
-2.18
-2.41
-1.43
Diluted EPS
-0.60
-1.48
-2.18
-2.41
-1.43
Basic Average Shares
121,814.1470
116,112.8910
93,654.2430
70,580.9490
61,485.2050
Diluted Average Shares
121,814.1470
116,112.8910
93,654.2430
70,580.9490
61,485.2050
Total Expenses
114,290.0000
207,812.0000
230,348.0000
168,901.0000
88,938.0000
Net Income from Continuing & Discontinued Operation
-74,619.0000
-171,670.0000
-204,212.0000
-170,060.0000
-88,045.0000
Normalized Income
-74,120.0000
-162,957.0000
-204,212.0000
-170,060.0000
-88,045.0000
Interest Income
9,770.0000
12,073.0000
2,883.0000
65.0000
424.0000
Interest Expense
4,019.0000
4,073.0000
3,328.0000
1,267.0000
359.0000
Net Interest Income
5,751.0000
8,000.0000
-445.0000
-1,202.0000
65.0000
EBIT
-70,182.0000
-167,597.0000
-200,884.0000
-168,793.0000
-87,686.0000
EBITDA
-68,507.0000
-166,080.0000
-199,957.0000
-167,938.0000
-86,676.0000
Reconciled Depreciation
1,675.0000
1,517.0000
927.0000
855.0000
1,010.0000
Net Income from Continuing Operation Net Minority Interest
-74,619.0000
-171,670.0000
-204,212.0000
-170,060.0000
-88,045.0000
Total Unusual Items Excluding Goodwill
-499.0000
-8,713.0000
--
--
--
Total Unusual Items
-499.0000
-8,713.0000
--
--
--
Normalized EBITDA
-68,008.0000
-157,367.0000
-199,957.0000
-167,938.0000
-86,676.0000
12/31/2020 - 7/4/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SCP.F Scancell Holdings plc
0.0960
+16.36%
 
4YL.F Nanoform Finland Oyj
1.2720
-2.90%
 
6XP.SG Xspray Pharma AB (publ)
2.9600
-6.03%
 
SCNLF Scancell Holdings plc
0.1800
0.00%
 
2105.HK Laekna, Inc.
12.500
-1.57%
 
XSPRAY.ST Xspray Pharma AB (publ)
29.25
-15.34%
 
SCLP.L Scancell Holdings plc
10.10
+3.59%
 
NRX.V NurExone Biologic Inc.
0.6800
+4.62%
 
BIXT Bioxytran, Inc.
0.0984
+15.58%
 
5CV.DE CureVac N.V.
4.2660
+9.61%